Quick Answer
KALA BIO, Inc. reported Operating Income Loss of -$40.98 million for the year ending 2024.
- KALA BIO, Inc. showed a decrease of -3.3% in Operating Income Loss from 2023 to 2024.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$9.65 million | Q3 2016: -$9.75 million | Q1 2017: -$9.57 million | Q2 2017: -$9.63 million | Q3 2017: -$9.53 million | Q1 2018: -$11.14 million | Q2 2018: -$14.52 million | Q3 2018: -$15.50 million | Q1 2019: -$24.05 million | Q2 2019: -$22.41 million | Q3 2019: -$21.57 million | Q1 2020: -$20.13 million | Q2 2020: -$21.28 million | Q3 2020: -$25.84 million | Q1 2021: -$28.31 million | Q2 2021: -$29.05 million | Q3 2021: -$26.07 million | Q1 2022: -$30.91 million | Q2 2022: -$25.97 million | Q3 2022: -$14.57 million | Q1 2023: -$11.68 million | Q2 2023: -$9.60 million | Q3 2023: -$8.76 million | Q1 2024: -$11.93 million | Q2 2024: -$9.61 million | Q3 2024: -$9.99 million | Q1 2025: -$10.67 million | Q2 2025: -$11.03 million | Q3 2025: -$7.24 million.
- Over the full 10 years of available data (2015 to 2024), KALA BIO, Inc.'s Operating Income Loss has declined by 157.0%.
- Historical annual values: Fiscal year 2024: -$40.98 million | Fiscal year 2023: -$39.66 million | Fiscal year 2022: -$81.71 million | Fiscal year 2021: -$130.25 million | Fiscal year 2020: -$96.23 million | Fiscal year 2019: -$88.22 million | Fiscal year 2018: -$64.72 million | Fiscal year 2017: -$39.88 million | Fiscal year 2016: -$32.67 million | Fiscal year 2015: -$15.95 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: